British authorities “AZ vaccine receives additional data to prove the effectiveness of the elderly”

At Churchill Hospital in Oxford, England, an 82-year-old grandfather is receiving the first vaccine for Corona 19 jointly developed by Oxford University and AstraZeneca. © AFP=News1 © News1 Reporter Dongmyeong Woo

Reuters reported on the 5th (local time) that the UK medical regulatory authorities have submitted additional clinical trial data that the novel coronavirus infection (Corona 19) vaccine developed by the British pharmaceutical company AstraZeneca is effective even in the elderly.

In the UK, after the first AstraZeneca vaccine was approved by the Medicines and Health Care Product Regulatory Authority (MHRA) in December of last year, the vaccine is being vaccinated for all ages, but some European countries say that additional data are needed for the elderly aged 65 years. Showed.

Sir Münir Pirmohamed, chairman of the UK Government’s Working Group Committee on Human Medicines Specialists, said, “As additional clinical trials are underway, additional data from AstraZeneca are coming in, which once again shows efficacy in the elderly.” There is no” he said.

He explained that the elderly are showing strong immune responses, and most importantly, the AstraZeneca vaccine and Pfizer-Bio&Tech’s vaccine are preventing serious illness and death.

In addition, AstraZeneca and Oxford University said the vaccine had similar efficacy in the first identified mutation in southern England.

“Data shows that the AstraZeneca vaccine is not only from the original virus, but also from a new mutation (B.1.1.7) that has caused a surge in confirmed cases in the UK since the end of 2020,” said Professor Andrew Pollard, chief investigator of the University of Oxford Vaccine Research Group. It has been shown to protect,” he said.

Vaccine co-developers Sarah Gilbert, a professor at Oxford University, predicts that the vaccine works for the UK mutation, but may need to be changed to accommodate new mutations that may emerge in the future.

[email protected]